How Much Upside is Left in Pliant Therapeutics, Inc. (PLRX)? Wall Street Analysts Think 106%Zacks Investment Research • 08/15/22
Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/08/22
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/08/22
Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 08/01/22
How Much Upside is Left in Pliant Therapeutics, Inc. (PLRX)? Wall Street Analysts Think 142%Zacks Investment Research • 07/28/22
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing CholangitisGlobeNewsWire • 07/21/22
Pliant Therapeutics Announces Pricing of Upsized $200.0 Million Public OfferingGlobeNewsWire • 07/12/22
Pliant Therapeutics (PLRX) Up on Positive Data From Lung Disease StudyZacks Investment Research • 07/12/22
Pliant Therapeutics, Inc. (PLRX) Stock Jumps 159%: Will It Continue to Soar?Zacks Investment Research • 07/12/22
Pliant's stock gains 41% after sharing positive data about its fibrosis therapy candidateMarket Watch • 07/11/22
Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary FibrosisGlobeNewsWire • 07/10/22
Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022 Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical TrialGlobeNewsWire • 06/24/22
Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular DystrophiesGlobeNewsWire • 06/22/22